Conduct a nationwide epidemiological study of Rx drug diversion for non-medical u

开展全国非医疗机构处方药转移流行病学研究

• 批准号: 7938628
• 负责人: DOUGLAS CORRY MCDONALD
• 金额: $ 54.91万
• 依托单位: ABT ASSOCIATES, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7938628
• 关键词: Age; Algorithms; Area; Award; Back; Benzodiazepines; Carisoprodol; Censuses; Cereals; Characteristics; Cities; Code; Communities; Computational algorithm; Computer software; County; Data; Data Set; Digit structure; Drug Prescriptions; Drug usage; Education; Employee; Employment; Epidemiologic Studies; Epidemiology; Ethnic Origin; Federal Government; Foundations; Funding; Health; Household; Housing; Income; Individual; Investments; Knowledge; Language; Link; Market Research; Marketing; Measures; Medical; Methods; Monitor; Names; Narcotic Analgesics; Patients; Pattern; Pharmaceutical Preparations; Pharmacy facility; Physicians; Population; Population Characteristics; Prevalence; Procedures; Public Health; Race; Records; Reporting; Research; Resource Allocation; Resources; Rural; Schedule; Single-Parent Family; Structure; Subgroup; Surveillance Program; Surveys; Time; United States National Institutes of Health; base; cost; data mining; design; dosage; health care delivery; hypnotic; improved; innovation; metropolitan; misuse of prescription only drugs; non-drug; programs; public health relevance; skills; socioeconomics; suburb; tool; trend

DESCRIPTION (provided by applicant): Abt Associates Inc. proposes a two-year project to develop and implement an ongoing Rx Drug Diversion Surveillance Program that will provide epidemiological data at the national and sub-national levels for 2008. The principal aim will be to estimate the diversion from retail pharmacies of 25 different controlled prescription drugs, most of which are scheduled and are known to be abused. Estimates will be developed of the numbers of individuals diverting these drugs for non-medical use, the numbers of prescriptions involved, the amounts of drugs so diverted (measured in dosage units and, separately, days supply), and the proportions of all dispensed prescriptions of each specific drug that are diverted. Combining these estimates with population data from U.S. census, prevalence rates (per 100,000 residents) will be developed for each of the 25 drugs at several levels: national, regional, state, county, town/city and, where meaningful, at the sub- city level. Estimates will also be developed for other geographical areas, such as rural/urban/suburban areas and largest 20 metropolitan areas. Socio-economic data from the 2000 U.S. census will be used to characterize the populations in these various geographical areas, and the relationships among prevalence rates and these contextual characteristics will be examined. This will provide a means for fine-grained analyses of the prevalence of prescription drug diversion in various areas of the nation and in various population subgroups. The study will exploit proprietary datasets developed for market research purposes, which are unique because information about prescriptions dispensed, patients, pharmacies, and prescribing physicians have been linked by means of HIPAA-compliant procedures. Computer algorithms will be developed to mine these data in search of suspicious patterns-combinations of patient/prescriber/prescription/pharmacy characteristics-indicative of diversion. Prevalence estimates so derived will be compared to estimates of drug use reported in other surveys and monitoring programs. In addition to developing estimates for 2008, the project will lay the foundation for an ongoing surveillance program (which will require separate funding). Patient-linked data are available back to 2001 and could be added subsequently. Going forward, prevalence estimates could be developed on an annual basis with continuously augmented data, and the program could be expanded to include other prescription drugs. This platform would therefore provide the scientific community with a rich dataset and powerful analytic tools to study diversion and misuse of prescription drugs throughout the nation and over time. PUBLIC HEALTH RELEVANCE: This two-year study and the ongoing surveillance program will support improvements in public health and health care delivery. Public investments in treatment capacity depend in part upon accurate estimation of trends in substance misuse at local levels, and more accurate estimates of diverted prescription drugs in these local illicit markets may improve these resource allocation decisions.

描述（由申请人提供）：Abt Associates Inc.建议开展一个为期两年的项目，以制定和实施一个正在进行的处方药物转移监测方案，该方案将提供2008年国家和国家以下各级的流行病学数据。主要目的是估计25种不同的受管制处方药从零售药房转移的情况，其中大部分是附表所列和已知被滥用的药物。将对将这些药物转用于非医疗用途的个人数量、所涉处方数量、转用的药物数量（分别以剂量单位和日供应量衡量）以及转用的每种特定药物的所有处方的比例进行估计。将这些估计数与美国人口普查的人口数据相结合，将在国家、地区、州、县、镇/市以及（如有意义）次城市一级确定25种药物中每种药物的流行率（每100，000居民）。还将为其他地理区域，如农村/城市/郊区和最大的20个大都市地区编制估计数。2000年美国人口普查的社会经济数据将用于描述这些不同地理区域的人口特征，并将研究患病率与这些背景特征之间的关系。这将为精细分析全国各地区和各人口亚组的处方药转移流行情况提供一种手段。 该研究将利用为市场研究目的开发的专有数据集，这些数据集是独一无二的，因为有关处方、患者、药房和处方医生的信息已通过符合HIPAA的程序联系起来。将开发计算机算法来挖掘这些数据，以寻找可疑模式-患者/处方者/处方/药房特征的组合-指示转移。由此得出的流行率估计数将与其他调查和监测方案中报告的毒品使用估计数进行比较。 除了对2008年进行评估外，该项目还将为正在进行的监测计划奠定基础（这将需要单独的资金）。与患者相关的数据可追溯到2001年，并可随后添加。展望未来，流行率估计可以在每年的基础上不断增加的数据，该计划可以扩大到包括其他处方药。因此，该平台将为科学界提供丰富的数据集和强大的分析工具，以研究全国各地和一段时间内处方药的转移和滥用。 公共卫生相关性：这项为期两年的研究和正在进行的监测计划将支持改善公共卫生和医疗保健服务。对治疗能力的公共投资部分取决于对地方一级药物滥用趋势的准确估计，对这些地方非法市场中被转移的处方药进行更准确的估计可能会改进这些资源分配决定。